secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001682852-25-000002
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna: 2024 sales $3.0-3.1B; 2025 revenue guided $1.5-2.5B, down ~40%; CMV trial misses early efficacy
--------------------------------------------------------------------------------

- 2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.
- 2025 revenue guidance $1.5-2.5B (mostly H2); expects year-end cash ~$6.0B.
- Accelerating cost cuts: $1B cash-cost reduction in 2025, additional $0.5B in 2026.
- CMV vaccine Phase 3 DSMB: early efficacy not met; study continues blinded. Final data expected 2025.
- Next-gen COVID BLA accepted (PDUFA May 31, 2025); RSV vaccine for high-risk adults filed; flu/COVID combo filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/0001682852-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000002/mrna-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001682852-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer